Concepedia

Wendy L. Sawicki

WL

Statistics

Publications

6

Citations

338

H-Index

6

Active since

1973

Affiliations

Yale University(Current)

Rutgers Cancer Institute

Wendy L. Sawicki is an author at Yale University specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

1973–1987

6

Publications

6

Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil.

Joseph R. Bertino, Wendy L. Sawicki, C. A. Lindquist et al. · PubMed · 1977 · 189 citations

, , +11

2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a potent non-classical folate antagonist inhibitor—I

Joseph R. Bertino, Wendy L. Sawicki, Barbara A. Moroson et al. · Biochemical Pharmacology · 1979 · 79 citations

, , +5

Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs.

Eleanor C. Weir, Arlene R. Cashmore, Robert N. Dreyer et al. · PubMed · 1982 · 33 citations

, , +12

The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.

Roland T. Skeel, Wendy L. Sawicki, Arlene R. Cashmore et al. · PubMed · 1973 · 15 citations

, , +9

Potent inhibitory activity of trimethoxyquine (tmq), "nonclassical" 2,4, diaminoquinazoline, on mammalian dna synthesis. Abstr.

Joseph Bertino, Wendy L. Sawicki · The Mouseion at the JAXlibrary (Jackson Laboratory) · 1977 · 12 citations

, , +6

1–5 of 6